|
An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) Clinical research trials and An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD). An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) clinical trial. Human subjects frequently get the finest healthcare available for their An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD) An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD)
An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD)
For Condition: Age-Related Maculopathies,Age-Related Maculopathy,Maculopathy, Age-Related,Maculopathies, Age-Related,Macular Degeneration
Status: Recruiting
Sponsor(s): Alcon Research ,
Synopsis: To demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.
Total Enrollment:
Location and Contact Information:
Europe *Recruiting*
, ,
Recruiting
New Zealand *Recruiting*
, ,
Recruiting
Additional Information:
Study ID Numbers: C-02-27;
Study Start Date:
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00051129
Other Maculopathies, Age-Related Studies:
1. Age-Related Macular Degeneration and Cataract
2. Phase I Study of Corticosteroid Treatment of Ill-defined Choroidal Neovascularization in Age-related Macular Degeneration
3. Submacular Surgery Trials (SST)
4. Genetic Factors in Age-Related Macular Degeneration
5. Preventing Depression in Patients with Macular Degeneration
Related Studies:
Other Maculopathies, Age-Related Clinical Trials
Other Clinical Trials
Other Clinical Trials
An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD)
|
|
|
|
|
|
|
|